je.st
news
Tag: proofofconcept
Oilex completes proof-of-concept objectives for Cambay field in India
2014-12-09 01:00:00| Hydrocarbons Technology
Australian oil and gas exploration firm Oilex has completed proof-of-concept objectives for the commercial development of the Cambay field in India.
Tags: field
india
objectives
completes
Purdue team demonstrates proof-of-concept of H2Bioil process; liquid fuel range hydrocarbons from biomass
2014-11-17 11:55:43| Green Car Congress
Tags: range
process
team
liquid
Interim Data from Proof-of-Concept Study of Merck's Investigational...
2014-11-10 08:38:26| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: data
study
interim
investigational
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
Researchers successfully engineer E. coli to produce renewable propane; proof-of-concept
2014-09-04 20:30:25| Green Car Congress
Tags: produce
successfully
researchers
engineer